4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Spyre Therapeutics, Inc. (SYRE) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 112 employees. Its market capitalization is roughly $9 billion. In the fiscal year ended 2025-12-31, SYRE reported $0M in revenue and ($155M) in net income.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $2M |
| Operating Income (EBIT) | ($220M) | ($209M) | ($129M) | ($85M) |
| Net Income | ($155M) | ($208M) | ($339M) | ($84M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($76M) | ($57M) | ($57M) | ($52M) | ($54M) | — |
| Net Income | ($69M) | ($62M) | ($11M) | ($37M) | ($45M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $778M | $608M | $342M | $71M | — |
| Total Liabilities | $62M | $91M | $158M | $21M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SYRE viewer.
About TickerBase · Data methodology & sources